Quercetin attenuates the ischemia reperfusion induced COX-2 and MPO expression in the small intestine mucosa

Tóth, Štefan; Jonecová, Zuzana; Čurgali, Kristína; Maretta, M.; Šoltés, Ján; Švaňa, Martin; Kalpadikis, Theodore; Čaprnda, Martin; Adamek, Mariusz; Rodrigo, Luı́s; Kružliak, Peter

doi:10.1016/j.biopha.2017.08.038

Cited by 26 publications

(27 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Kaempferol-3-O-rutinoside inhibits macrophages from secreting inflammatory factors, such as TNF, like IL-6, TNF-α, COX-2 and iNOS (24). Quercetin reduces COX-2 and MPO expression in intestine ischemia reperfusion injury (25). The NF-κB pathway is inhibited by Quercetin (26).…”

Section: Figurementioning

confidence: 99%

Study on the mechanism of the Modified Ginseng-Schisandra Decoction (MGSD) in the treatment of recurrent respiratory tract infection (RRTI) based on network pharmacology

Cui

Zhan

et al. 2021

Transl Pediatr

View full text Add to dashboard Cite

Background: The aim of this study was to investigate the mechanism of Modified Ginseng-Schisandra Decoction in the treatment of recurrent respiratory tract infection (RRTI) using network pharmacology.Methods: To screen the active ingredients of A Modified Ginseng-Schisandra Decoction, TCMSP, TCMID, Batman-TCM and PubChem database were applied. To predict the targets of active ingredients on RRTI, TCMSP, Pubmed, OMIM, Drug Bank, GAD and TTD database were used. The compoundstherapeutic target network was constructed with Cytoscape 3.7.2 software. The STRING database was used to construct a protein-protein interaction (PPI) network, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was used to identify potential signal pathways.Results: The 3 main active ingredients of Modified Ginseng-Schisandra Decoction obtained by screening were quercetin, kaempferol, and isoflavone; the main therapeutic targets were PTGS2, ESR1, AR, PPARG, NOS2, and others. Based on the PPI network, we found that the targets of Modified Ginseng-Schisandra Decoction were significantly enriched in (FDR <0.01) cancer pathway, tumor necrosis factor (TNF) signaling pathway, hypoxia-inducible factor (HIF-1) signaling pathway, and others.Conclusions: Modified Ginseng-Schisandra Decoction can treat RRTI primarily through acting in the signal transduction of some key nodes of cancer pathway and TNF pathway. It exerts a direct or indirect influence on multiple signaling pathways, and has the characteristics of multicomponent, multitarget, and multichannel action.

show abstract

Section: Figurementioning

confidence: 99%

Study on the mechanism of the Modified Ginseng-Schisandra Decoction (MGSD) in the treatment of recurrent respiratory tract infection (RRTI) based on network pharmacology

Cui

Zhan

et al. 2021

Transl Pediatr

View full text Add to dashboard Cite

show abstract

“…Among them, the compounds that showed most closely bound to PTGS2, PPARG, NOS2, and NRC31 were quercetin, gallic acid-3-O-(6′-O-galloyl)-glucoside, quercetin, and stigmasterol, respectively (Figure 3). Quercetin has BioMed Research International been reported to decrease the expression and activity of COX-2 induced by ischemia reperfusion or arsenite [42,43]. In addition, quercetin inhibited inflammatory response induced by LPS through iNOS/FAK/paxillin or p38/iNOS/NF-kappaB signaling pathway [44][45][46].…”

Section: Verification Of the Corementioning

confidence: 99%

Mechanism of Action of Bu-Fei-Yi-Shen Formula in Treating Chronic Obstructive Pulmonary Disease Based on Network Pharmacology Analysis and Molecular Docking Validation

Chen

Jiao

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Objective. To explore the mechanism of action of Bu-Fei-Yi-Shen formula (BFYSF) in treating chronic obstructive pulmonary disease (COPD) based on network pharmacology analysis and molecular docking validation. Methods. First of all, the pharmacologically active ingredients and corresponding targets in BFYSF were mined by the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database, the analysis platform, and literature review. Subsequently, the COPD-related targets (including the pathogenic targets and known therapeutic targets) were identified through the TTD, CTD, DisGeNet, and GeneCards databases. Thereafter, Cytoscape was employed to construct the candidate component-target network of BFYSF in the treatment of COPD. Moreover, the cytoHubba plug-in was utilized to calculate the topological parameters of nodes in the network; then, the core components and core targets of BFYSF in the treatment of COPD were extracted according to the degree value (greater than or equal to the median degree values for all nodes in the network) to construct the core network. Further, the Autodock vina software was adopted for molecular docking study on the core active ingredients and core targets, so as to verify the above-mentioned network pharmacology analysis results. Finally, the Omicshare database was applied in enrichment analysis of the biological functions of core targets and the involved signaling pathways. Results. In the core component-target network of BFYSF in treating COPD, there were 30 active ingredients and 37 core targets. Enrichment analysis suggested that these 37 core targets were mainly involved in the regulation of biological functions, such as response to biological and chemical stimuli, multiple cellular life processes, immunity, and metabolism. Besides, multiple pathways, including IL-17, Toll-like receptor (TLR), TNF, and HIF-1, played certain roles in the effect of BFYSF on treating COPD. Conclusion. BFYSF can treat COPD through the multicomponent, multitarget, and multipathway synergistic network, which provides basic data for intensively exploring the mechanism of action of BFYSF in treating COPD.

show abstract

“…It is reported that PTGS2 (also known as COX-2) was involved in podocyte injury and various renal pathological processes such as renal interstitial brosis, showing a potential therapeutic target against lupus nephritis-induced nephropathy [74,75]. Coincidentally, several studies have proved that PTGS2 was inhibited by beta-sitosterol, quercetin, and berberine inhibiting the expression of PTGS2 in mouse colitis, the small intestine mucosa of rats, and human endometrial cells, respectively [76][77][78]. ESR1 is a potential therapy target for proteinuria caused by IgA nephropathy through the proliferation of glomerular mesangial cells [79].…”

Section: Ptgs2 Esr1 and Nos2 As The Key Targets Of Sbtagainstmentioning

confidence: 99%

Identifying Synergistic Mechanisms of Multiple Ingredients in Shuangbai Tablets against Proteinuria by Virtual Screening and a Network Pharmacology Approach

Hao

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Shuangbai Tablets (SBT), a traditional herbal mixture, has shown substantial clinical efficacy. However, a systematic mechanism of its active ingredients and pharmacological mechanisms of action against proteinuria continues being lacking. A network pharmacology approach was effectual in discovering the relationship of multiple ingredients and targets of the herbal mixture. This study aimed to identify key targets, major active ingredients, and pathways of SBT against proteinuria by network pharmacology approach combined with thin layer chromatography (TLC). Human phenotype (HP) disease analysis, gene ontology (GO) analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, and molecular docking were used in this study. To this end, a total of 48 candidate targets of 118 active ingredients of SBT were identified. Network analysis showed PTGS2, ESR1, and NOS2 to be the three key targets, and beta-sitosterol, quercetin, and berberine were the three major active ingredients; among them one of the major active ingredients, quercetin, was discriminated by TLC. These results of the functional enrichment analysis indicated that the most relevant disease including these 48 candidate proteins is proteinuria, SBT treated proteinuria by sympathetically regulating multiple biological pathways, such as the HIF-1, RAS, AGE-RAGE, and VEGF signaling pathways. Additionally, molecular docking validation suggested that major active ingredients of SBT were capable of binding to HIF-1A and VEGFA of the main pathways. Consequently, key targets, major active ingredients, and pathways based on data analysis of SBT against proteinuria were systematically identified confirming its utility and providing a new drug against proteinuria.

show abstract

Quercetin attenuates the ischemia reperfusion induced COX-2 and MPO expression in the small intestine mucosa

Cited by 26 publications

References 44 publications

Study on the mechanism of the Modified Ginseng-Schisandra Decoction (MGSD) in the treatment of recurrent respiratory tract infection (RRTI) based on network pharmacology

Study on the mechanism of the Modified Ginseng-Schisandra Decoction (MGSD) in the treatment of recurrent respiratory tract infection (RRTI) based on network pharmacology

Mechanism of Action of Bu-Fei-Yi-Shen Formula in Treating Chronic Obstructive Pulmonary Disease Based on Network Pharmacology Analysis and Molecular Docking Validation

Identifying Synergistic Mechanisms of Multiple Ingredients in Shuangbai Tablets against Proteinuria by Virtual Screening and a Network Pharmacology Approach

Contact Info

Product

Resources

About